Novartis’ Gilenya patent loss sets MS market up for battle with early generics

Novartis’ bid to fend off early Gilenya generics has failed in court. The Swiss drugmaker, attempting to salvage a 2026 patent, lost that fight at the U.S... »

Credit Suisse execs take 40 percent bonus cuts after outcry

Credit Suisse’s chief and other top executives offered on Friday to have their bonuses slashed by 40 percent, following investor concern over the size of ... »

Pay for Failure: Tidjane Thiam’s Credit Suisse CEO compensation for 2016, 11.9 Mio CHF

  Tidjane Thiam’s compensation for 2016 shows Credit Suisse’s tin ear.   The Swiss bank’s board has granted Mr. Thiam, its chief executive, 11.9 milli... »

More top executives flee Zurich Insurance

There is another exit at the top management level of Zurich Insurance. After Claudio Gienal’s departure last December, the communications and  marketing h... »

Bernstein expects Credit Suisse 2017 cap hike, no Swiss unit listing

  Credit Suisse could opt for a 5 billion Swiss franc ($4.9 billion) capital increase instead of floating a minority stake of its Swiss business, Bernstein... »

ABB – inadequate Governance – $100 million internal fraud

Swiss engineering group ABB (ABBN.S) on Wednesday said it fell victim to a “sophisticated criminal scheme” at its South Korean subsidiary, with the ... »

crucif AI – Artificial Intelligence for detecting ethical deficits and dysfunctional behavior

WHISTLE-BLOWING: A civic duty

Enhanced Corporate Governance through Independent Oversight

Culinary Corner